Reported 17 days ago
Despite the stock market being generally overpriced, investors can still find good bargains. The Motley Fool highlights three healthcare stocks—CRISPR Therapeutics, Gilead Sciences, and Pfizer—that are currently undervalued. CRISPR offers potential growth through its groundbreaking treatments, Gilead is expected to boost its revenues with new HIV treatments while paying a solid dividend, and Pfizer, despite facing some challenges, remains a solid investment due to its low valuation and commitment to dividend growth.
Source: YAHOO